Description of the urine analysis:

Deoxypyridinoline (DPD or Pyrilinks-D) is a structural cross-link molecule that stabilizes type I collagen in bone tissue. When bone is broken down by specialized cells called osteoclasts—a process known as resorption—DPD is released into the bloodstream and excreted unchanged in the urine. Unlike other markers, DPD is not affected by diet (it isn’t found in food) and is highly specific to bone tissue. This makes it one of the most reliable laboratory tools for measuring the current speed of bone loss, allowing doctors to detect early signs of osteoporosis or monitor how well bone-strengthening medications are working.

What does the analysis represent?

• Goal: To quantify the rate of bone matrix breakdown by measuring DPD concentration in the urine.
• Primary Application: Early diagnosis of osteoporosis, monitoring bone health in postmenopausal women, and assessing the effectiveness of anti-resorptive therapies (like bisphosphonates).
• Method: Competitive chemiluminescence immunoassay (CLIA) or Enzyme-linked immunosorbent assay (ELISA).

Recommendations for the Test (General)

• Time: The most accurate results are obtained from the second morning void (collected between 7:00 AM and 10:00 AM).
• Hygiene: Standard external cleansing of the genital area is required before sample collection.
• Collection: Use a sterile, light-protected (amber) container or wrap a standard container in foil.
• Specific Rules: Avoid intense physical exercise for 24 hours before the test. It is critical to protect the sample from light, as UV rays can degrade the DPD molecule and lead to falsely low results.

What can affect the results?

• Factors altering levels: Recent bone fractures (within the last 6 months); age (children have naturally higher levels due to growth); pregnancy; severe kidney disease; and exposure of the urine sample to direct sunlight.

When to take the test?

• Recommendations: For women entering menopause, patients with a history of low-impact fractures, or those being treated for bone diseases to evaluate if the medication is successfully slowing down bone loss.
• Preparation: The test is usually performed while the patient is on their regular diet, as DPD is not influenced by food intake.

How to interpret the results?

Evaluating your DPD levels is a specialized medical task performed by your endocrinologist, rheumatologist, or orthopedist. Because DPD levels vary according to the time of day, results are typically corrected for “urinary creatinine” to ensure accuracy. A high level indicates that bone is being broken down faster than it is being rebuilt, but it does not specify the cause. Your doctor will synthesize this data with a Bone Density Scan (DEXA) and other mineral markers. Only a professional can determine if an elevated result requires a change in medication or if it represents a normal physiological response to healing or growth.

Possible further investigations

• DEXA Scan (Bone Density): To measure the current structural strength of the bones.
• Osteocalcin: A blood marker that measures the rate of new bone formation.
• Vitamin D (25-OH) & Calcium: To assess the raw materials available for bone health.
• Parathyroid Hormone (PTH): To check the hormonal regulation of calcium and bone metabolism.
• Consultation with a Rheumatologist or Endocrinologist.

When does the next step make sense?

If DPD levels are significantly elevated, the next logical step is to perform a DEXA scan to see if the high resorption rate has already led to low bone mass. Catching accelerated bone loss early allows for preventative treatment that can significantly reduce the risk of future fractures.

👉 If necessary, you can discuss the results of the analysis with a specialist, such as an endocrinologist (Doctors – TAMC).